124 related articles for article (PubMed ID: 3480669)
1. [CA 19-9 in neoplasms. Comparison with CEA].
Nakad A; Jonard P; Geubel A; Warzee P; Coppens JP; Dehennin JP; Dive C
Acta Gastroenterol Belg; 1987; 50(1):36-44. PubMed ID: 3480669
[No Abstract] [Full Text] [Related]
2. Comparative effectiveness of the tumour diagnostics, CA 19-9, CA 125 and carcinoembryonic antigen in patients with diseases of the digestive system.
Sakamoto K; Haga Y; Yoshimura R; Egami H; Yokoyama Y; Akagi M
Gut; 1987 Mar; 28(3):323-9. PubMed ID: 3471687
[TBL] [Abstract][Full Text] [Related]
3. [Diagnostic value of a new serum marker of human digestive cancer: the carbohydrate antigen 19.9; comparison with the carcinoembryonic antigen].
Olsson NO; Crimet-Montange D; Martin F
Gastroenterol Clin Biol; 1985 Mar; 9(3):206-11. PubMed ID: 3859449
[TBL] [Abstract][Full Text] [Related]
4. [Clinical evaluation of the tumor marker CA 19-9 in comparison with carcinoembryonic antigen (CEA) in surgical pre- and postoperative diagnosis].
Lorenz M; Happ J; Hottenrott C; Maul FD; Baum RP; Hör G; Encke A
Nuklearmedizin; 1986 Feb; 25(1):9-14. PubMed ID: 3459133
[TBL] [Abstract][Full Text] [Related]
5. [Usefulness of the determination of CA 19-9 in the follow-up of patients with gastroenteric neoplasms in comparison to CEA].
Pecchio F; Piantino P; Oliaro A; Rapellino M; Ricci E; Aimo G; Obert R
Minerva Med; 1986 Nov; 77(42-43):1973-81. PubMed ID: 3464850
[TBL] [Abstract][Full Text] [Related]
6. [A new carbohydrate antigen CA19-9 associated with malignancies of digestive system. II. Serum levels of CA19-9 in various digestive diseases and their clinical significance].
Yamanaka T; Kitagawa Y; Seki H; Kimura K; Sakurabayashi I; Kawai T
Rinsho Byori; 1984 Jul; 32(7):786-92. PubMed ID: 6594536
[No Abstract] [Full Text] [Related]
7. Serum sialyl-Tn antigen levels in patients with digestive cancers.
Motoo Y; Kawakami H; Watanabe H; Satomura Y; Ohta H; Okai T; Makino H; Toya D; Sawabu N
Oncology; 1991; 48(4):321-6. PubMed ID: 1891175
[TBL] [Abstract][Full Text] [Related]
8. The combined use of CA 19-9 and carcino-embryonic antigen (CEA) in malignancies of the gastrointestinal tract.
Staab HJ
Acta Gastroenterol Belg; 1987; 50(1):29-35. PubMed ID: 3480668
[No Abstract] [Full Text] [Related]
9. [Evaluation of the measurement of serum carcinoembryonic antigen (CEA) levels using monoclonal antibody].
Yoneshima M; Sawabu N; Kidani H; Takemori Y; Toya D; Okai T; Hattori N; Ogino T; Mai M
Gan No Rinsho; 1985 Aug; 31(10):1311-7. PubMed ID: 4057566
[TBL] [Abstract][Full Text] [Related]
10. Comparison of a new tumour marker CA 242 with CA 19-9, CA 50 and carcinoembryonic antigen (CEA) in digestive tract diseases.
Kuusela P; Haglund C; Roberts PJ
Br J Cancer; 1991 Apr; 63(4):636-40. PubMed ID: 2021550
[TBL] [Abstract][Full Text] [Related]
11. [Immunohistochemical evaluation of several tumor markers (CEA, ferritin, Ca) and their correlation with estro-progestin receptor state in neoplasms].
Forti E; Wolf D; Melia M
Pathologica; 1985; 77(1049):241-9. PubMed ID: 3913892
[No Abstract] [Full Text] [Related]
12. [Serum level of tumor markers (antigen Ca 19-9, CEA, ferritin) in digestive tumors. Their diagnostic usefulness].
Jovin G; Stănel I; Popovici I; Oproiu A
Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Med Interna; 1988; 40(3):223-9. PubMed ID: 2904162
[No Abstract] [Full Text] [Related]
13. [Prognostic value of tumor markers in cases of colorectal cancer: CEA and CA 19-9].
Desaive C; Servais R; Collette J; Denis D; Reginster JY; Franchimont P
Acta Gastroenterol Belg; 1987; 50(1):65-78. PubMed ID: 3480671
[No Abstract] [Full Text] [Related]
14. Comparison of CA-50, a new tumour marker, with carcinoembryonic antigen (CEA) and alpha-fetoprotein (AFP) in patients with gastrointestinal diseases.
Kuusela P; Haglund C; Roberts PJ; Jalanko H
Br J Cancer; 1987 Jun; 55(6):673-6. PubMed ID: 2441731
[TBL] [Abstract][Full Text] [Related]
15. [TAA combination in digestive neoplasms].
Ciarniello P; Latella G; Fusco A; Giannoni MF; Citone G; Catani M
Minerva Med; 1986 Mar; 77(13):501-2. PubMed ID: 3458034
[No Abstract] [Full Text] [Related]
16. [CA 12-5 in cancer of the digestive tract. A comparison with CA 19-9 and CEA in cancer of the pancreas and colon].
Klapdor R; Klapdor U; Bahlo M; Dallek M; Kremer B; van Ackeren H; Schreiber HW; Greten H
Dtsch Med Wochenschr; 1984 Dec; 109(51-52):1949-54. PubMed ID: 6595110
[TBL] [Abstract][Full Text] [Related]
17. [The value of tissue polypeptide antigen (TPA) levels in malignant digestive system pathology].
de Clippele C; Pluygers E; Baldewyns P; Beauduin M; Therasse G; de Neve de Roden A; Hermans J; Majois F; Pourbaix A
Acta Gastroenterol Belg; 1987; 50(1):52-62. PubMed ID: 3425169
[No Abstract] [Full Text] [Related]
18. [Serum levels and clinical evaluation of CA 19-9 in various diseases].
Toyama K; Noto M; Sakaguchi T; Adachi K; Mitomi H; Okada N; Ootaka H; Nakazawa H; Hara E
Gan No Rinsho; 1985 Mar; 31(3):293-8. PubMed ID: 2582158
[TBL] [Abstract][Full Text] [Related]
19. [CA 19-9 in early cancers of the bronchi. Comparison with the carcinoembryogenic antigen].
Vindimian M; Lafitte JJ; Wattre P
Biomed Pharmacother; 1987; 41(4):191-5. PubMed ID: 3476162
[TBL] [Abstract][Full Text] [Related]
20. Tumour marker CA 125 in patients with digestive tract malignancies.
Haglund C; Kuusela P; Roberts P; Jalanko H
Scand J Clin Lab Invest; 1991 May; 51(3):265-270. PubMed ID: 1715601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
